Merus to Present at Canaccord Genuity’s 44th Annual Growth Conference
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company specializing in innovative multispecific antibodies, has announced its participation in Canaccord Genuity's 44th Annual Growth Conference. Bill Lundberg, M.D., President and CEO of Merus, will present on Tuesday, August 13, 2024, from 9:00-9:25 a.m. ET.
The presentation will be webcast live on the Investors page of the Merus website and will remain available for a time after the event. This conference provides Merus with an opportunity to showcase its progress in developing Biclonics® and Triclonics®, their full-length multispecific antibody platforms, to potential investors and industry professionals.
Merus N.V. (Nasdaq: MRUS), una società oncologica in fase clinica specializzata in anticorpi multispecifici innovativi, ha annunciato la sua partecipazione alla 44ª Conferenza Annuale sulla Crescita di Canaccord Genuity. Bill Lundberg, M.D., Presidente e CEO di Merus, presenterà martedì 13 agosto 2024, dalle 9:00 alle 9:25 ET.
La presentazione sarà trasmessa in diretta sulla pagina per gli investitori del sito web di Merus e resterà disponibile per un certo periodo dopo l'evento. Questa conferenza offre a Merus l'opportunità di mettere in mostra i suoi progressi nello sviluppo di Biclonics® e Triclonics®, le loro piattaforme di anticorpi multispecifici a lunghezza intera, a potenziali investitori e professionisti del settore.
Merus N.V. (Nasdaq: MRUS), una empresa de oncología en etapa clínica especializada en anticuerpos multispecíficos innovadores, ha anunciado su participación en la 44ª Conferencia Anual de Crecimiento de Canaccord Genuity. Bill Lundberg, M.D., Presidente y CEO de Merus, presentará el martes 13 de agosto de 2024, de 9:00 a 9:25 a.m. ET.
La presentación será transmitida en vivo en la página de Inversores del sitio web de Merus y estará disponible por un tiempo después del evento. Esta conferencia brinda a Merus la oportunidad de mostrar su progreso en el desarrollo de Biclonics® y Triclonics®, sus plataformas de anticuerpos multispecíficos de longitud completa, a posibles inversores y profesionales de la industria.
Merus N.V. (Nasdaq: MRUS)는 혁신적인 다특이성 항체를 전문으로 하는 임상 단계의 항암 회사로, Canaccord Genuity의 제44회 연례 성장 컨퍼런스에 참여한다고 발표했습니다. Bill Lundberg, M.D.는 Merus의 사장이자 CEO로서 2024년 8월 13일, 화요일, 오전 9시부터 9시 25분까지 ET에 발표할 예정입니다.
이번 발표는 Merus 웹사이트의 투자자 페이지에서 라이브 스트리밍될 예정이며, 이벤트 후 일정 기간 동안 이용 가능합니다. 이 컨퍼런스는 Merus가 Biclonics® 및 Triclonics®라는 전체 길이의 다특이성 항체 플랫폼 개발에 대한 진행 상황을 잠재 투자자 및 산업 전문가에게 보여줄 수 있는 기회를 제공합니다.
Merus N.V. (Nasdaq: MRUS), une entreprise d'oncologie en phase clinique spécialisée dans les anticorps multispecifiques innovants, a annoncé sa participation à la 44e Conférence Annuelle de Croissance de Canaccord Genuity. Bill Lundberg, M.D., Président et CEO de Merus, fera une présentation le mardi 13 août 2024, de 9h00 à 9h25 ET.
La présentation sera diffusée en direct sur la page des investisseurs du site Web de Merus et restera disponible pendant un certain temps après l'événement. Cette conférence offre à Merus l'occasion de présenter ses avancées dans le développement de Biclonics® et Triclonics®, ses plateformes d'anticorps multispecifiques de pleine longueur, à des investisseurs potentiels et des professionnels de l'industrie.
Merus N.V. (Nasdaq: MRUS), ein klinisches Onkologieunternehmen, das sich auf innovative multispezifische Antikörper spezialisiert hat, hat seine Teilnahme an der 44. jährlichen Wachstums-Konferenz von Canaccord Genuity bekannt gegeben. Bill Lundberg, M.D., Präsident und CEO von Merus, wird am Dienstag, den 13. August 2024, von 9:00 bis 9:25 Uhr ET präsentieren.
Die Präsentation wird live über das Internet übertragen und auf der Investoren-Seite der Merus-Website verfügbar sein und eine gewisse Zeit nach der Veranstaltung zur Verfügung stehen. Diese Konferenz bietet Merus die Möglichkeit, seinen Fortschritt bei der Entwicklung von Biclonics® und Triclonics®, ihren vollständigen multispezifischen Antikörper-Plattformen, potenziellen Investoren und Fachleuten der Branche zu präsentieren.
- None.
- None.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will present at Canaccord Genuity’s 44th Annual Growth Conference on Tuesday, August 13, 2024 from 9:00-9:25 a.m. ET.
The webcast of the presentation will be contemporaneously available on the Investors page of the Company's website. The archived presentation will also be available there for a limited time after the event.
About Merus
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website, X and LinkedIn.
Multiclonics®, Biclonics® and Triclonics® are registered trademarks of Merus N.V.
FAQ
When is Merus (MRUS) presenting at Canaccord Genuity's 44th Annual Growth Conference?
Who will be representing Merus (MRUS) at the Canaccord Genuity conference?
Where can I watch the Merus (MRUS) presentation at the Canaccord Genuity conference?
What does Merus (MRUS) specialize in developing?
